Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERNANASDAQ:HOWLNASDAQ:LVTXNASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAEterna Therapeutics$0.22+5.4%$0.24$0.15▼$2.63$11.29M4.792.79 million shs210,780 shsHOWLWerewolf Therapeutics$0.89-0.7%$1.02$0.60▼$6.89$40.21M0.48388,350 shs221,294 shsLVTXLAVA Therapeutics$1.31-5.1%$1.25$0.85▼$3.20$36.30M0.46161,567 shs25,601 shsOKUROnKure Therapeutics$2.60-1.9%$4.17$2.50▼$20.00$34.93M0.3582,823 shs108,496 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAEterna Therapeutics+5.42%+16.76%-5.96%-61.84%-87.59%HOWLWerewolf Therapeutics-0.71%-3.08%-13.52%-35.46%-86.06%LVTXLAVA Therapeutics-5.07%0.00%+2.75%+37.89%-52.19%OKUROnKure Therapeutics-1.89%-10.03%-45.15%-54.06%+259,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERNAEterna Therapeutics1.4392 of 5 stars0.05.00.00.02.71.70.6HOWLWerewolf Therapeutics2.3381 of 5 stars3.52.00.00.01.43.30.6LVTXLAVA Therapeutics2.3658 of 5 stars3.05.00.00.03.30.00.6OKUROnKure Therapeutics3.3728 of 5 stars3.70.00.00.03.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERNAEterna Therapeutics 0.00N/AN/AN/AHOWLWerewolf Therapeutics 3.00Buy$9.00910.44% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17141.73% UpsideOKUROnKure Therapeutics 3.40Buy$32.331,143.59% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, HOWL, LVTX, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.503/18/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.003/12/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/12/2025HOWLWerewolf TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/11/2025OKUROnKure TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $30.002/27/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$2.00 ➝ $1.50(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERNAEterna Therapeutics$582K19.39N/AN/A$0.41 per share0.53HOWLWerewolf Therapeutics$1.89M21.18N/AN/A$3.08 per share0.29LVTXLAVA Therapeutics$11.98M2.88N/AN/A$1.95 per share0.67OKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%5/13/2025 (Estimated)HOWLWerewolf Therapeutics-$37.37M-$1.66N/AN/AN/A-578.80%-58.83%-38.45%5/2/2025 (Estimated)LVTXLAVA Therapeutics-$41.97M-$0.93N/AN/AN/AN/A-62.22%-29.37%5/20/2025 (Estimated)OKUROnKure Therapeutics-$77.39M-$6.57N/AN/AN/AN/A-51.17%-47.11%5/6/2025 (Estimated)Latest ERNA, HOWL, LVTX, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025LVTXLAVA Therapeutics-$0.37N/AN/AN/AN/AN/A5/6/2025N/AOKUROnKure Therapeutics-$1.41N/AN/AN/AN/AN/A5/2/2025Q1 2025HOWLWerewolf Therapeutics-$0.44N/AN/AN/AN/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million3/11/2025Q4 2024HOWLWerewolf Therapeutics-$0.43-$0.46-$0.03-$0.46$1.00 millionN/A3/10/2025Q4 2024OKUROnKure Therapeutics-$0.86-$1.37-$0.51-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERNAEterna TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERNAEterna TherapeuticsN/A0.480.48HOWLWerewolf Therapeutics0.2910.1010.10LVTXLAVA TherapeuticsN/A5.365.36OKUROnKure TherapeuticsN/A23.7123.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERNAEterna Therapeutics70.55%HOWLWerewolf Therapeutics64.84%LVTXLAVA TherapeuticsN/AOKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipERNAEterna Therapeutics4.49%HOWLWerewolf Therapeutics21.10%LVTXLAVA Therapeutics0.79%OKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERNAEterna Therapeutics1052.25 million5.17 millionNo DataHOWLWerewolf Therapeutics4044.83 million35.16 millionOptionableLVTXLAVA Therapeutics6026.31 million26.08 millionOptionableOKUROnKure TherapeuticsN/A13.44 million2.75 millionN/AERNA, HOWL, LVTX, and OKUR HeadlinesRecent News About These CompaniesOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%April 6, 2025 | aaii.comAisling Capital Management LP Invests $762,000 in OnKure Therapeutics (NASDAQ:OKUR)April 3, 2025 | marketbeat.comHighbridge Capital Management LLC Makes New $3.44 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)March 29, 2025 | marketbeat.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 12, 2025 | tipranks.comOnKure boosts R&D spending with cancer trial underwayMarch 12, 2025 | bizwest.comOnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)March 10, 2025 | markets.businessinsider.comOnKure Therapeutics price target lowered to $30 from $35 at OppenheimerMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Progress on PIKture-01 Trial and Expands PI3Ka Franchise with Upcoming Development Candidate AnnouncementMarch 10, 2025 | quiverquant.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | globenewswire.comOnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor ConferencesMarch 4, 2025 | globenewswire.comDeep Track Capital, LP Acquires Shares in OnKure Therapeutics IncFebruary 14, 2025 | gurufocus.comHighbridge Capital Management LLC Acquires Significant Stake in OnKure Therapeutics IncFebruary 7, 2025 | gurufocus.comJonesTrading Reaffirms Their Buy Rating on OnKure Therapeutics (OKUR)February 6, 2025 | markets.businessinsider.comVanguard Group Inc's Strategic Acquisition of OnKure Therapeutics SharesJanuary 31, 2025 | gurufocus.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Up 10.42%January 31, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTop 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing Market2 Penny Stocks With $10 Potential By Thomas Hughes | April 16, 2025View 2 Penny Stocks With $10 Potential 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskBig Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIBy Jeffrey Neal Johnson | April 7, 2025View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AI2 Strong Utilities Plays With Booming Earnings and Room to GrowBy Nathan Reiff | April 24, 2025View 2 Strong Utilities Plays With Booming Earnings and Room to GrowERNA, HOWL, LVTX, and OKUR Company DescriptionsEterna Therapeutics NASDAQ:ERNA$0.22 +0.01 (+5.42%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.21 -0.01 (-3.70%) As of 04/25/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Werewolf Therapeutics NASDAQ:HOWL$0.89 -0.01 (-0.71%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.92 +0.03 (+3.51%) As of 04/25/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.LAVA Therapeutics NASDAQ:LVTX$1.32 -0.06 (-4.35%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.OnKure Therapeutics NASDAQ:OKUR$2.60 -0.05 (-1.89%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.60 0.00 (-0.19%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
